■最近的研究表明,降脂药(LLA)可以减少慢性牙周炎,但目前尚不清楚这种益处是否适用于2型糖尿病(T2D)患者。
■我们评估了西班牙裔成人T2D患者使用LLA与牙周炎之间的关联。
■这是一项横断面观察性研究。
■我们评估了253名40-65岁的波多黎各人使用LLA和牙周参数与参与牙周炎和糖尿病研究中使用降脂药的T2D的相关性。参与者被归类为(A)非-或<1年,1-4年,或(c)>4年。主要结果包括具有探测袋深度(PPD)4mm的部位的三元百分比,次要结果包括具有临床附着丧失(CAL)4mm的部位的三元百分比。根据年龄调整的多项逻辑回归模型,性别,吸烟状况,教育,腰围,糖化血红蛋白A1C(HbA1c),探查时出血,考官,和抗炎药用于评估相关性。
■LLA(92.5%,他汀类药物)被52%的参与者使用。LLA使用1-4年与较低的PPD4mm(OR:0.22,p=0.005;高与低三分位数)或较低的CAL4mm(OR:0.33,p=0.02,中与低三分位数),与LLA最小或无用的人相比。对于使用LLA>4年的参与者来说,这种关联消失了。患有牙周病的LLA使用者超过4年的HbA1c升高(OR:1.36,p=0.05)。
■使用LLA1-4年与较低的牙周参数值相关,而使用LLA最少。在使用LLA>4年用户的人群中不存在这种关联,但与其他参与者相比,这些参与者的血糖控制较差.在这项横断面研究中,在T2D个体中,LLA使用1-4年与牙周严重度参数值较低相关,这一发现可能有助于澄清这些药物在该人群中获益的一些争议.
2型糖尿病患者的降脂药和牙周参数值较低•降脂药(LLA),如他汀类药物,据报道可以减少慢性牙周炎,使糖尿病患者成为这种治疗的理想人选,因为他们的口腔疾病患病率很高。•在患有2型糖尿病(T2D)的西班牙裔成年人中评估了LLA使用与牙周炎之间的关联。•短期使用LLA(但不是长期使用)与T2D患者牙周参数值较低相关。•对于长期使用LLA,高血糖水平与牙周炎的高值相关。•Thus,在研究设计限制下,这一发现可能提供临床意义,并可能有助于澄清关于LLA在人类中使用益处的一些争议.•此外,长期使用LLA的牙周患者的血糖水平较高,这表明需要仔细监测这些患者.
UNASSIGNED: Recent studies suggest that lipid-lowering agents (LLA) may reduce chronic periodontitis, but it is unknown whether this benefit extends to people with type 2 diabetes (T2D).
UNASSIGNED: We assessed the association between LLA use and periodontitis in Hispanic adults with T2D.
UNASSIGNED: This was a cross-sectional observational study.
UNASSIGNED: We assessed the association of LLA use and periodontal parameters in 253 Puerto Ricans 40-65 years with T2D who participated in the Lipid-Lowering agents use in Periodontitis and Diabetes Study study. Participants were classified as (a) none- or <1 year, (b) 1-4 years, or (c) >4 years. The primary outcome consists of a tertile percent of sites with probing pocket depth (PPD) ⩾ 4 mm and the secondary outcome includes tertiles of percent sites with clinical attachment loss (CAL) ⩾ 4 mm. Multinomial logistic regression models adjusted for age, gender, smoking status, education, waist circumference, glycosylated hemoglobin A1C (HbA1c), bleeding on probing, examiner, and anti-inflammatory agents were used to estimate the association.
UNASSIGNED: LLA (92.5%, statins) was used by 52% of participants. LLA use 1-4 years was associated with lower odds of PPD ⩾ 4 mm (OR: 0.22, p = 0.005; high versus low tertile) or lower odds of CAL ⩾ 4 mm (OR: 0.33, p = 0.02, middle versus low tertile), compared to those with LLA minimal or no use. This association was lost for participants who used LLA for >4 years. LLA users for >4 years with periodontal disease had elevated HbA1c (OR: 1.36, p = 0.05).
UNASSIGNED: The use of LLA for 1-4 years was associated with lower values of periodontal parameters versus minimal LLA use. This association was not present among people using LLA > 4 years users, but these participants had poorer glycemic control compared to other participants. In this cross-sectional study, the finding that LLA use 1- 4 years is associated with lower values of periodontal parameters of severity in T2D individuals may help clarify some of the controversies regarding the benefit of these medications in this population.
Lipid-lowering agents and lower values of periodontal parameters in individuals with type 2 diabetes • Lipid-lowering agents (LLA), such as statins, are reported to reduce chronic periodontitis, making individuals with diabetes ideal candidates for this treatment due to their high prevalence of oral disease.• The association between LLA use and periodontitis was assessed among Hispanic adults with type 2 diabetes (T2D).• Short-term LLA use (but not long-term use) was associated with lower values of periodontal parameters in individuals with T2D.• For long-term LLA use, high glycemic level was associated with high values of periodontitis.• Thus, under the study design limitations, the finding may provide clinical implications and may help clarify some of the controversies regarding the benefits of LLA use in humans.• Furthermore, the higher glycemic levels for periodontal patients with long-term LLA use points to the need to monitor these patients carefully.